Restaging Transurethral Resection of HG Ta Bladder Tumors: A Risk-Adapted Approach
PJ Hensley(The University of Texas MD Anderson Cancer Center), A. M. Kamat(The University of Texas MD Anderson Cancer Center), Supriya Nagaraju(The University of Texas MD Anderson Cancer Center), H. Barton Grossman(The University of Texas MD Anderson Cancer Center), Justin T. Matulay(Levine Cancer Institute), Nathan A. Brooks(Eli Lilly (United States)), Neema Navai(The University of Texas MD Anderson Cancer Center), Kelly K. Bree(The University of Texas MD Anderson Cancer Center), Colin P. Dinney(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
|European Urology|2014|297
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
|The Journal of Urology|2019|190
Assessment of Luminal and Basal Phenotypes in Bladder Cancer
|Scientific Reports|2020|176